[go: up one dir, main page]

DE60008234D1 - Liposomenzusammensetzungen zur verbesserten wirkstoffzurückhaltung - Google Patents

Liposomenzusammensetzungen zur verbesserten wirkstoffzurückhaltung

Info

Publication number
DE60008234D1
DE60008234D1 DE60008234T DE60008234T DE60008234D1 DE 60008234 D1 DE60008234 D1 DE 60008234D1 DE 60008234 T DE60008234 T DE 60008234T DE 60008234 T DE60008234 T DE 60008234T DE 60008234 D1 DE60008234 D1 DE 60008234D1
Authority
DE
Germany
Prior art keywords
active substance
liposome compositions
improved active
liposomes
fluoroquinolone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60008234T
Other languages
English (en)
Other versions
DE60008234T2 (de
Inventor
S Guo
Radwan Kiwan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of DE60008234D1 publication Critical patent/DE60008234D1/de
Publication of DE60008234T2 publication Critical patent/DE60008234T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
DE60008234T 1999-04-29 2000-04-28 Liposomenzusammensetzungen zur verbesserten wirkstoffzurückhaltung Expired - Fee Related DE60008234T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13155399P 1999-04-29 1999-04-29
US131553P 1999-04-29
PCT/US2000/011625 WO2000066126A2 (en) 1999-04-29 2000-04-28 Liposome compositions for improved drug retention

Publications (2)

Publication Number Publication Date
DE60008234D1 true DE60008234D1 (de) 2004-03-18
DE60008234T2 DE60008234T2 (de) 2004-12-30

Family

ID=22449950

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60008234T Expired - Fee Related DE60008234T2 (de) 1999-04-29 2000-04-28 Liposomenzusammensetzungen zur verbesserten wirkstoffzurückhaltung

Country Status (17)

Country Link
EP (1) EP1176962B1 (de)
JP (1) JP2002543134A (de)
KR (1) KR100766753B1 (de)
CN (1) CN1172670C (de)
AT (1) ATE259231T1 (de)
AU (1) AU767474B2 (de)
CA (1) CA2371483A1 (de)
DE (1) DE60008234T2 (de)
DK (1) DK1176962T3 (de)
ES (1) ES2214269T3 (de)
HK (1) HK1044122B (de)
HU (1) HUP0201644A3 (de)
IL (2) IL146113A0 (de)
MX (1) MXPA01010977A (de)
NO (1) NO320629B1 (de)
WO (1) WO2000066126A2 (de)
ZA (1) ZA200108907B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0111279D0 (en) * 2001-05-10 2001-06-27 Nycomed Imaging As Radiolabelled liposomes
WO2003032947A2 (en) * 2001-09-06 2003-04-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem A method for preparing liposome formulations with a predefined release profile
CA2821167C (en) 2004-05-03 2016-06-28 Merrimack Pharmaceuticals, Inc. Drug delivery liposomes containing anionic polyols or anionic sugars
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
MX2007002462A (es) * 2004-09-03 2007-10-10 Piedmont Pharmaceuticals Llc Metodo para el tratamiento de transmembrana y prevencion de la otitis media.
EP1932517A3 (de) * 2006-12-11 2008-07-16 Universiteit Utrecht Holding B.V. Liposomen beinhaltend Polyphenolderivaten und deren Verfahren zur Nachbeladung
JP5351076B2 (ja) * 2010-02-26 2013-11-27 杏林製薬株式会社 オンライン固相抽出による生体試料液中薬剤成分の定量方法
CN102309448B (zh) * 2010-06-29 2014-07-09 中国人民解放军军事医学科学院毒物药物研究所 一种肺部给药的环丙沙星药用组合物及其制备方法
JP5848511B2 (ja) * 2011-03-29 2016-01-27 株式会社コーセー リポソーム組成物、並びにそれを用いた化粧料、皮膚外用剤及びその製造方法
CN102627642A (zh) * 2012-03-19 2012-08-08 南京洵安医药科技有限公司 莫西沙星金属配合物及其制药用途
US10220095B2 (en) * 2013-03-15 2019-03-05 Taiwan Liposome Company, Ltd Controlled drug release liposome compositions and methods thereof
WO2017066726A1 (en) 2015-10-16 2017-04-20 Merrimack Pharmaceuticals, Inc. Stabilizing camptothecin pharmaceutical compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61130239A (ja) * 1984-11-30 1986-06-18 Dai Ichi Seiyaku Co Ltd 複合体
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5227372A (en) * 1990-03-07 1993-07-13 Children's Medical Center Corporation Method for retaining ophthalmological agents in ocular tissues
JPH0447351A (ja) * 1990-06-12 1992-02-17 Nec Corp シングルチップマイクロコンピュータ
JP2944759B2 (ja) * 1995-05-24 1999-09-06 アルコン ラボラトリーズ，インコーポレイテッド 抗菌性組成物
ATE331739T1 (de) * 1998-04-28 2006-07-15 Inex Pharmaceuticals Corp Polyanionische polymere mit verbesserter fusogenfähigkeit

Also Published As

Publication number Publication date
IL146113A0 (en) 2002-07-25
AU767474B2 (en) 2003-11-13
HK1044122A1 (en) 2002-10-11
HK1044122B (en) 2004-11-26
AU4500600A (en) 2000-11-17
DE60008234T2 (de) 2004-12-30
NO20015246D0 (no) 2001-10-26
EP1176962B1 (de) 2004-02-11
KR100766753B1 (ko) 2007-10-17
CN1351495A (zh) 2002-05-29
DK1176962T3 (da) 2004-06-14
MXPA01010977A (es) 2002-07-22
ATE259231T1 (de) 2004-02-15
KR20020011978A (ko) 2002-02-09
HUP0201644A3 (en) 2004-05-28
NO320629B1 (no) 2006-01-02
EP1176962A2 (de) 2002-02-06
CN1172670C (zh) 2004-10-27
WO2000066126A3 (en) 2001-04-05
CA2371483A1 (en) 2000-11-09
ZA200108907B (en) 2002-12-24
WO2000066126A2 (en) 2000-11-09
JP2002543134A (ja) 2002-12-17
ES2214269T3 (es) 2004-09-16
IL146113A (en) 2006-07-05
NO20015246L (no) 2001-12-28
HUP0201644A2 (hu) 2002-12-28

Similar Documents

Publication Publication Date Title
DE60008234D1 (de) Liposomenzusammensetzungen zur verbesserten wirkstoffzurückhaltung
AU5905400A (en) Methods and compositions for delivery and retention of active agents to lymph nodes
EP1226104A4 (de) Phenoxycarbonsäureverbindungen und zusammensetzungen zur verabreichung aktiver wirkstoffe
PT915898E (pt) Forma i cristalina de claritromicina
WO2000071125A3 (de) Pharmazeutisches präparat mit dem wirkstoff diamorphin und seine verwendung in einem verfahren zur behandlung der opiatsucht
EP1100522A4 (de) Verabreichung aktiver wirkstoffe über die lunge
AU4460900A (en) Carrier patch for the delivery of agents to the skin
NZ505514A (en) Method of manufacturing a wound dressing for the application of honey
EE200300151A (et) Ravimitena kasutatavad antikolinergikumid ning meetodid nende valmistamiseks
WO2001027099A3 (en) Bicyclic compounds composition and method for stabilizing the same
AU7079700A (en) Improved stable formulations of ace inhibitors, and methods for preparation thereof
WO2003051275A3 (en) Benzodiazepine derivatives, preparation thereof and use thereof
DE60040190D1 (de) Hydrogel zusammensetzungen, geeignet zur verzögerten freisetzung von makromolekülen sowie verfahren zur herstellung derselben.
EP1167354A3 (de) Racemisches Huperzin A
DK1274399T3 (da) Liposomer indeholdende en indesluttet forbindelse i overmættet oplösning
AU2002214389A1 (en) Pharmaceutical composition containing honey for the treatment of wounds
DE60043261D1 (de) Verfahren zur herstellung von phenylessigsäure derivaten
AU2420001A (en) Methods and compositions for the treatment of pain
DE60237388D1 (de) Verfahren zur herstellung von zusammensetzungen mit erhöhtem gehalt von salzen pharmazeutisch aktiver rotamere
DE60034843D1 (de) Verfahren zur Herstellung von L-arginin
EA200000172A2 (ru) Способ получения стимуляторов секреции гормонов роста
CA2393483A1 (en) Stable pharmaceutical preparations comprising a benzimidazole and process for their production
PT1181300E (pt) Derivados 6-o-carbamato de cetolido
DE60112381D1 (de) Verfahren zur Herstellung von Ethylen-Vinylacetatcopolymeren
DE50010585D1 (de) Verfahren zur Herstellung von Dioxazin-Verbindungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee